& Shahid, M
As a result, previously anovulatory women may resume regular cycles sooner than expected
Common gastrointestinal effects reported with GLP-1 therapy include: Nausea (commonly reported, especially during dose escalation) Constipation or diarrhoea Abdominal discomfort or bloating Reduced appetite and early satiety Regarding bowel movement colour specifically, changes in stool colour are not listed as adverse effects in UK SmPCs for GLP-1 receptor agonists
Furthermore, the genomic landscape revealed a network of enzymes capable of interconverting different B 6 vitamers, including pyridoxine 5-phosphate oxidase (PdxH), sugar phosphatases, pyridoxine 4-dehydrogenase, pyridoxal kinase, and PMP oxidase
Thats what my obesity medicine specialist recognized
The regeneration of GSH after an APAP dose is also affected by the concentration of glutamate in the liver and it is known that supplementation of rats with glutamine prior to and APAP over dose acts to preserve GSH levels